|
1
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Knizetova P, Ehrmann J, Hlobilkova A,
Vancova I, Kalita O, Kolar Z and Bartek J: Autocrine regulation of
glioblastoma cell cycle progression, viability and radioresistance
through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle. 7:2553–2561.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lichtenberger BM, Tan PK, Niederleithner
H, Ferrara N, Petzelbauer P and Sibilia M: Autocrine VEGF signaling
synergizes with EGFR in tumor cells to promote epithelial cancer
development. Cell. 140:268–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hamerlik P, Lathia JD, Rasmussen R, Wu Q,
Bartkova J, Lee M, Moudry P, Bartek J Jr, Fischer W, Lukas J, et
al: Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma
stem-like cell viability and tumor growth. J Exp Med. 209:507–520.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bieche I, Vacher S, Vallerand D, Richon S,
Hatem R, De Plater L, Dahmani A, Némati F, Angevin E, Marangoni E,
et al: Vasculature analysis of patient derived tumor xenografts
using species-specific PCR assays: Evidence of tumor endothelial
cells and atypical VEGFA-VEGFR1/2 signalings. BMC Cancer.
14:1782014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Andersen S, Donnem T, Al-Shibli K, Al-Saad
S, Stenvold H, Busund LT and Bremnes RM: Prognostic impacts of
angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is
strongly associated with Ang-2. PLoS One. 6:e197732011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jantus-Lewintre E, Sanmartín E, Sirera R,
Blasco A, Sanchez JJ, Tarón M, Rosell R and Camps C: Combined
VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and
prognostic implications in patients with advanced NSCLC. Lung
Cancer. 74:326–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Donnem T, Al-Shibli K, Andersen S, Al-Saad
S, Busund LT and Bremnes RM: Combination of low vascular
endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and
high lymphocyte infiltration is a strong and independent favorable
prognostic factor in patients with nonsmall cell lung cancer.
Cancer. 116:4318–4325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takenaka K, Katakura H, Chen F, Ogawa E,
Adachi M, Wada H and Tanaka F: The ratio of membrane-bound form
Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and
prognosis in non-small cell lung cancer. Cancer Lett. 246:34–40.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons
DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, et
al: miR-200 Inhibits lung adenocarcinoma cell invasion and
metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie
Z, Chen SL, Huang Y, Zhang AY, Yan JF, et al: KDR expression is
associated with the stage and cigarette smoking of the patients
with lung cancer. J Cancer Res Clin Oncol. 133:635–642. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seto T, Higashiyama M, Funai H, Imamura F,
Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic
value of expression of vascular endothelial growth factor and its
flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung
Cancer. 53:91–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Volm M, Koomägi R and Mattern J:
Prognostic value of vascular endothelial growth factor and its
receptor Flt-1 in squamous cell lung cancer. Int J Cancer.
74:64–68. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bild AH, Yao G, Chang JT, Wang Q, Potti A,
Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al:
Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature. 439:353–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Raponi M, Zhang Y, Yu J, Chen G, Lee G,
Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y, et al: Gene
expression signatures for predicting prognosis of squamous cell and
adenocarcinomas of the lung. Cancer Res. 66:7466–7472. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee ES, Son DS, Kim SH, Lee J, Jo J, Han
J, Kim H, Lee HJ, Choi HY, Jung Y, et al: Prediction of
recurrence-free survival in postoperative non-small cell lung
cancer patients by using an integrated model of clinical
information and gene expression. Clin Cancer Res. 14:7397–7404.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuen HF, Gunasekharan VK, Chan KK, Zhang
SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG,
Rudland PS, et al: RanGTPase: A candidate for Myc-mediated cancer
progression. J Natl Cancer Inst. 105:475–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sanmartín E, Sirera R, Usó M, Blasco A,
Gallach S, Figueroa S, Martínez N, Hernando C, Honguero A,
Martorell M, et al: A gene signature combining the tissue
expression of three angiogenic factors is a prognostic marker in
early-stage non-small cell lung cancer. Ann Surg Oncol. 21:612–620.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vieira JM, Ruhrberg C and Schwarz Q: VEGF
receptor signaling in vertebrate development. Organogenesis.
6:97–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 55:2542–2550. 2006. View Article : Google Scholar
|
|
23
|
Reck M, Kaiser R, Mellemgaard A, Douillard
JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I,
Liao M, et al: LUME-Lung 1 Study Group: Docetaxel plus nintedanib
versus docetaxel plus placebo in patients with previously treated
non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind,
randomised controlled trial. Lancet Oncol. 15:143–155. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fukumura D, Xavier R, Sugiura T, Chen Y,
Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, et al: Tumor
induction of VEGF promoter activity in stromal cells. Cell.
94:715–725. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang WC, Wu X, Peale FV, Lee CV, Meng YG,
Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, et al:
Cross-species vascular endothelial growth factor (VEGF)-blocking
antibodies completely inhibit the growth of human tumor xenografts
and measure the contribution of stromal VEGF. J Biol Chem.
281:951–961. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang SD, McCrudden CM, Meng C, Lin Y and
Kwok HF: The signifiance of combining VEGFA, FLT1 and KDR
expressions in colon cancer patient prognosis and predicting
response to bevacizumab. Onco Targets Ther. 8:835–843.
2015.PubMed/NCBI
|
